Should non-inferiority drug trials be banned altogether?

Drug Discovery Today

Volumn 18, Issue 11-12, 2013, Pages 601-604

  Wangge, Grace ^a   Klungel, Olaf H ^a   Roes, Kit C B ^b   De Boer, Anthonius ^a   Hoes, Arno W ^b   Knol, Mirjam J ^b,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

CLINICAL TRIAL (TOPIC); DRUG DETERMINATION; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; FUNDING; HUMAN; MEDICAL EXPERT; MEDICAL LITERATURE; NON INFERIORITY DRUG TRIAL; PRACTICE GUIDELINE; RESEARCH ETHICS; REVIEW;

CLINICAL TRIALS AS TOPIC; DRUG THERAPY; HUMANS; TREATMENT OUTCOME;

EID: 84878842428     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.01.003     Document Type: Review

References (28)

1. S. Garattini, and V. Bertele Non-inferiority trials are unethical because they disregard patients' interests Lancet 370 2007 1875 1877
2. G. Piaggio Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement J. Am. Med. Assoc. 295 2006 1152 1160
3. Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) Draft Guidance: Guidance for Industry Non-Inferiority Clinical Trials 2010 2010
4. G. Wangge Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review PLoS ONE 5 2010 e13550
5. Committee for Medicinal Products for Human Use (CHMP) Guideline on the Choice of the Non-inferiority Margin. EMEA/CPMP/EWP/2158/99 2005 2005
6. G. Wangge Interpretation and inference in noninferiority randomized controlled trials in drug research Clin. Pharmacol. Ther. 88 2010 420 423
7. G. Wangge The challenges of determining noninferiority margins: a case study of noninferiority randomized controlled trials of novel oral anticoagulants Can. Med. Assoc. J. 2012 [Epub ahead of print]
8. R.B.S. D'Agostino Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics Stat. Med. 22 2003 169 186
9. T.R. Fleming Current issues in non-inferiority trials Stat. Med. 27 2008 317 332
10. S. Everson-Stewart, and S.S. Emerson Bio-creep in non-inferiority clinical trials Stat. Med. 29 2010 2769 2780
11. A.J. Nunn The ethics of non-inferiority trials Lancet 371 2008 895
12. C. Chuang-Stein The ethics of non-inferiority trials Lancet 371 2008 895 896
13. A. Gandjour The ethics of non-inferiority trials Lancet 371 2008 895
14. E.Z. Soliman The ethics of non-inferiority trials Lancet 371 2008 895
15. M. Wonder Australian managed entry scheme: a new manageable process for the reimbursement of new medicines? Value Health 15 2012 586 590
16. P. Beryl, and W. Vach Is there a danger of "biocreep" with non-inferiority trials? Trials 12 Suppl. 1 2011 A29
17. A. Gayet-Ageron What differences are detected by superiority trials or ruled out by noninferiority trials? A cross-sectional study on a random sample of two-hundred two-arms parallel group randomized clinical trials BMC Med. Res. Methodol. 10 2010 93
18. M. Man-Son-Hing Determination of the clinical importance of study results J. Gen. Intern. Med. 17 2002 469 476
19. Peterson, L., "Clinical" Significance: "Clinical" Significance and "Practical" Significance are NOT the Same Things, Paper presented at the Annual Meeting of the Southwest Educational Research Association (New Orleans, LA, Feb 7, 2008)
20. T.C. Campbell An Introduction to clinical significance: an alternative index of intervention effect for group experimental designs J. Early Intervention 27 2005 210 227
21. Committee for Proprietary Medicinal Products (CPMP) Guideline on the Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections 1995
22. Committee for Medicinal Products for Human Use (CHMP) Guideline on Clinical Investigation of Medicinal Products in the Treatment of Diabetes Mellitus. CPMP/EWP/1080/00 Rev 1* 2011
23. Center for Drug Evaluation and Research (CDER) Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention Draft Guidance 2008
24. Committee for Medicinal Products for Human Use (CHMP) Guideline on the Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections. CPMP/EWP/558/95 Rev 2 2011
25. European Medicines Agency European Medicines Agency Guidance for Companies Requesting Scientific Advice and Protocol Assistance. EMEA-H-4260-01-Rev 6 2010
26. Pre-IND Consultation Program. Available at: http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/ InvestigationalNewDrugINDApplication/Overview/default.htm (accessed 05.09.12)
27. C.S. Miller Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Am. J. Cardiol. 110 2012 453 460
28. D.M. Sobieraj Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis Pharmacotherapy 32 2012 799 808